the effectiveness of treatment, and predict the therapeutic effect. Under these circumstances, it becomes crucial

of TAMs and their increasing number of biomarkers, indicating their predictive value for the clinical

utilized in clinical practice as reliable indicators of the disease. In addition to genetics, epigenetic

serve as noninvasive biomarkers, particularly useful for early cancer detection, follow-up of patients

and sensitive biomarkers such as ST2 and Pentraxin-3 (Ptx-3) have prediction potential in HF and primary

an epigenetic and genetic mechanism for the development of lung cancer. The current situation with the diagnosis

death, growth, differentiation, apoptosis, epigenetic regulation, and so on. Many lncRNAs have altered

for epigenetic signatures and aberrations associated with the risk of developing OP. Based on pyrosequencing

of cardiovascular biomarkers on predicting outcomes in COVID-19 patients is still unknown. Therefore, to investigate

adequate treatment improve prognosis. The ability to accurately predict the development of GC and start